Vascular events after stroke: Terutroban fails to PERFORM

The Lancet

Volumn 377, Issue 9782, 2011, Pages 1980-1982

  Lee, Meng ^a   Ovbiagele, Bruce ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; TERUTROBAN; TICLOPIDINE;

BRAIN ISCHEMIA; FOLLOW UP; HUMAN; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT FAILURE;

EID: 79958765190     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60708-3     Document Type: Note

References (12)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Bousser M-G, Amarenco P, Chamorro A, et al, on behalf of the PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; published online May 25. DOI:10.1016/S0140-6736(11)60600-4.
3. Hass WK, Easton JD, Adams HP Jr, et al, for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-07. (Pubitemid 19203874)
4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13. (Pubitemid 26402780)
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
6. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947-57. (Pubitemid 37430096)
7. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34: 840-48.
8. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
9. Shinohara Y, Katayama Y, Uchiyama S, et al, for the CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
10. Chen ZM, Sandercock P, Pan HC, et al, on behalf of the CAST and IST collaborative groups. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000; 31: 1240-49. (Pubitemid 30351240)
11. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-73. (Pubitemid 38252797)
12. Garcia Rodriguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76: 740-46.